Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
Authors:
- Mickaël HiligsmannMHMickaël Hiligsmann
- Jean-Yves ReginsterJRJean-Yves Reginster
Abstract
No abstract availableKeywords
Funding Information
- Amgen
This publication has 45 references indexed in Scilit:
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in OsteoporosisValue in Health, 2009
- Belgian Methodological Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement RequestsValue in Health, 2009
- Lifetime absolute risk of hip and other osteoporotic fracture in Belgian womenBone, 2008
- Health economics of osteoporosisBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference modelOsteoporosis International, 2006
- A meta-analysis of previous fracture and subsequent fracture riskBone, 2004
- Fracture risk following an osteoporotic fractureOsteoporosis International, 2003
- Treatment of established osteoporosis: a systematic review and cost-utility analysisHealth Technology Assessment, 2002
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000